Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Dyax and Defiante Farmaceutica, an affiliate of the pharmacutical group Sigma-Tau (Sigma-Tau), have expanded their partnerneship for the commercialization of Kalbitor (ecallantide)as a treatment for hereditary angioedema (HAE) accross Australia and New Zealand.
Subscribe to our email newsletter
In addition to receiving an upfront payment of $1m, which includes $500,000 in cash and $500,000 in equity shares at a 50% premium investment, Dyax is eligible for up to $2m in regulatory and commercialization milestones.
Dyax will also receive royalties equal to 41% of net sales of product, less cost of goods sold.
Consistent with the previous agreement, Sigma-Tau will pay the costs associated with regulatory approval and commercialization in these additional territories.
Dyax president and CEO Gustav Christensen said that expanding the agreement with Sigma-Tau Group enables us to advance the global commercialization strategy for Kalbitor and to make it available to HAE patients worldwide.